Our evaluation showed that the CXCR2 signalling pathway is a key driver of thyroid cancer cell motility and is a critical chemokine receptor targeted by AZD5069 via selective CXCR2 antagonism. This evidence concerns the gene CXCR2 and thyroid gland carcinoma.